| Market Cap | 2.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | -53.10% |
| Income | 3.07M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 6.00% |
| Sales | 42k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
| Dividend | N/A | Price/Book | 0.03 | EPS next 5Y | 7.00% | 52W High Chg | -89.00% |
| Recommedations | - | Quick Ratio | 15.88 | Shares Outstanding | 37.49M | 52W Low Chg | 2,100.00% |
| Insider Own | - | ROA | -228.91% | Shares Float | - | Beta | 6.52 |
| Inst Own | - | ROE | 111.59% | Shares Shorted/Prior | 18.48M/15.83M | Price | 0.00440 |
| Gross Margin | 497.62% | Profit Margin | 7,300.00% | Avg. Volume | 1,713 | Target Price | - |
| Oper. Margin | -2,438.10% | Earnings Date | - | Volume | 2,495 | Change | 4.76% |
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
| McNicoll Lewis Vlak | Sell | Mar 19, 13 |
| Lazard | Neutral | Feb 26, 13 |
| JMP Securities | Market Underperform | Feb 25, 13 |
| Piper Sandler | Neutral | Feb 25, 13 |
| Piper Sandler | Neutral | Feb 25, 13 |
| Stifel | Hold | Feb 25, 13 |
| McNicoll Lewis Vlak | Hold | Feb 25, 13 |
| JMP Securities | Market Outperform | Feb 8, 13 |
| Dawson James | Market Outperform | Nov 27, 12 |